Long Term Safety Throughout 18 month treatment period [clinicaltrials_resource:e6f4e2f193ec8ceb2ba9154a296b2320]

Long Term Safety Throughout 18 month treatment period [clinicaltrials_resource:e6f4e2f193ec8ceb2ba9154a296b2320]

10mg Tablet, oral Daily for 18 months
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:e6f4e2f193ec8ceb2ba9154a296b2320
Safety of Treatment of Uterine Fibroids With Asoprisnil [clinicaltrials:NCT00156208]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Long Term Safety Throughout 18 month treatment period [clinicaltrials_resource:e6f4e2f193ec8ceb2ba9154a296b2320]

10mg Tablet, oral Daily for 18 months
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:e6f4e2f193ec8ceb2ba9154a296b2320
Bio2RDF identifier
e6f4e2f193ec8ceb2ba9154a296b2320
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:e6f4e2f193ec8ceb2ba9154a296b2320
measure [clinicaltrials_vocabulary:measure]
time frame [clinicaltrials_vocabulary:time-frame]
Throughout 18 month treatment period
description
10mg Tablet, oral Daily for 18 months
identifier
clinicaltrials_resource:e6f4e2f193ec8ceb2ba9154a296b2320
title
Long Term Safety Throughout 18 month treatment period
@en
inDataset
type
label
Long Term Safety Throughout 18 ...... 4e2f193ec8ceb2ba9154a296b2320]
@en